search
Back to results

High Dose Dexamethasone Vs. Conventional Dose Prednisolone in Adult ITP

Primary Purpose

Idiopathic Thrombocytopenic Purpura

Status
Completed
Phase
Phase 3
Locations
Korea, Republic of
Study Type
Interventional
Intervention
Dexamethasone
Prednisolone
Sponsored by
Cooperative Study Group A for Hematology
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional treatment trial for Idiopathic Thrombocytopenic Purpura focused on measuring ITP

Eligibility Criteria

16 Years - undefined (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria :

  • a true thrombocytopenia on blood smear
  • adequate megakaryopoiesis on bone marrow examination
  • the absence of clinically apparent associated conditions or cause of thrombocytopenia
  • Age over 16 years
  • A platelet count of less than 30x109/L

Exclusion criteria :

  • previous treatment for ITP.
  • other causes of thrombocytopenia such as HIV infection, lymphproliferative disease, liver disease, or definite SLE.
  • Patients with life threatening bleeding and pregnant women should be excluded.

Sites / Locations

  • Asan Medical Center

Outcomes

Primary Outcome Measures

response rate and platelet count
Endpoint definitions and criteria for evaluation: This study is designed to compare the effectiveness of high dose dexamethasone with conventional dose prednisone for patient with ITP. The effectiveness will be evaluated in terms of response rate and platelet count at 6 months after the treatment

Secondary Outcome Measures

Full Information

First Posted
March 22, 2007
Last Updated
January 12, 2011
Sponsor
Cooperative Study Group A for Hematology
search

1. Study Identification

Unique Protocol Identification Number
NCT00451594
Brief Title
High Dose Dexamethasone Vs. Conventional Dose Prednisolone in Adult ITP
Official Title
A Randomized Controlled Multicentre Trial of High Dose Dexamethasone Versus Conventional Dose Prednisolone for Adults With Untreated Idiopathic Thrombocytopenic Purpura
Study Type
Interventional

2. Study Status

Record Verification Date
January 2011
Overall Recruitment Status
Completed
Study Start Date
September 2005 (undefined)
Primary Completion Date
December 2010 (Actual)
Study Completion Date
December 2010 (Actual)

3. Sponsor/Collaborators

Name of the Sponsor
Cooperative Study Group A for Hematology

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
To determine the long term effects of pulse high dose dexamethasone and conventional dose prednisolone in treatment of adult patients with ITP.
Detailed Description
Patients will be randomized to one of two study arms: dexamethasone 40 mg po daily for 4 consecutive days. If the platelet count drops below 30X109/L after response within 6 months, another four-day course of dexamethasone will be given, followed by 15 mg of prednisone daily, with gradual tapering (Arm 1). Prednisone 1 mg/kg po daily for 4-8 weeks, the drug is then decreased slowly over another few weeks (Arm 2).

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Idiopathic Thrombocytopenic Purpura
Keywords
ITP

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
157 (Actual)

8. Arms, Groups, and Interventions

Intervention Type
Drug
Intervention Name(s)
Dexamethasone
Other Intervention Name(s)
Dexa
Intervention Description
Pulse high dose dexamethasone (Arm 1) Patients will receive 40 mg of oral dexamethasone daily for four consecutive days. Other treatments should be considered if there was a platelet count of 30X109/L or less by day 14 If the patient had a platelet count of more than 30X109/L after four days of dexamethasone treatment, no further treatment will be given. If the platelet count drops below 30X109/L within the first 6 months, another four-day course of dexamethasone will be given, followed by 15 mg of prednisone daily, with gradual tapering. Patients whose platelet counts can not be maintained at 30X109/L will be offered other treatments.
Intervention Type
Drug
Intervention Name(s)
Prednisolone
Other Intervention Name(s)
PD
Intervention Description
Conventional dose prednisone (Arm 2) Prednisone, 1 mg/kg is started at diagnosis. If the platelet count is more than 100X109/L, the dose should be used for 4 weeks minimally and then tapered by 10 mg/1 wk until the dose reaches 0.5 mg/kg of body weight and by 5 mg/1 wk thereafter. (Ann Intern Med 1997, 126, 307-14). If the platelet count is between 30X109/L and 100X109/L, prednisone 1 mg/kg should be used for 8 weeks maximally and then tapered by 10 mg/2 wk until the dose reaches 0.5 mg/kg of body weight and by 5 mg/2 wk thereafter. Guideline of prednisone tapering Duration of prednisone treatment: 3-6 months
Primary Outcome Measure Information:
Title
response rate and platelet count
Description
Endpoint definitions and criteria for evaluation: This study is designed to compare the effectiveness of high dose dexamethasone with conventional dose prednisone for patient with ITP. The effectiveness will be evaluated in terms of response rate and platelet count at 6 months after the treatment
Time Frame
6 years

10. Eligibility

Sex
All
Minimum Age & Unit of Time
16 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria : a true thrombocytopenia on blood smear adequate megakaryopoiesis on bone marrow examination the absence of clinically apparent associated conditions or cause of thrombocytopenia Age over 16 years A platelet count of less than 30x109/L Exclusion criteria : previous treatment for ITP. other causes of thrombocytopenia such as HIV infection, lymphproliferative disease, liver disease, or definite SLE. Patients with life threatening bleeding and pregnant women should be excluded.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Sung Hwa Bae, professor
Organizational Affiliation
Daegu Catholic Univertity Hospital, ROK
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Jung-Hee Lee, professor
Organizational Affiliation
Asan Medical Center, ROK
Official's Role
Principal Investigator
Facility Information:
Facility Name
Asan Medical Center
City
Seoul
State/Province
Songpa-gu
ZIP/Postal Code
138-736
Country
Korea, Republic of

12. IPD Sharing Statement

Links:
URL
http://www.google.co.kr
Description
A RANDOMIZED CONTROLLED MULTICENTER TRIAL OF HIGH DOSE DEXAMETHASONE VERSUS CONVENTIONAL DOSE PREDNISONE FOR ADULTS WITH UNTREATED IDIOPATHIC THROMBOCYTOPENIC PURPURA

Learn more about this trial

High Dose Dexamethasone Vs. Conventional Dose Prednisolone in Adult ITP

We'll reach out to this number within 24 hrs